Join Dr. Philip McCarthy as he explains the development of central nervous system toxicity after cytokine-release syndrome (CRS), and also whether CRS affects CAR T cells.

In this activity, Dr. Philip McCarthy discusses cytokine-release syndrome and the most common treatment approaches.

Dr. Holstein explains the risk of developing an SPM on lenalidomide maintenance vs. the benefit of maintenance in delaying progression or death from myeloma, and how to counsel patients.

Dr. Holstein reviews the impact maintenance therapy has on patient outcomes, and what factors you must consider when prescribing maintenance therapy.

Dr. Richardson provides a brief update on recent developments in CAR-T therapy in patients with multiple myeloma, and what we can see on the horizon.

Dr. Richardson discusses an area of unmet need in relapsed/refractory multiple myeloma: how to identify treatment options for so-called "quad-refractory" patients.

Dr. Davies details the tools and technologies used to define and detect minimal residual disease, and discusses how to proceed once you know your patient's MRD status.

Dr. McCarthy explains the evolving recommendations for how and when to use herpes zoster vaccine in multiple myeloma patients, both active and newly diagnosed.

Dr. Raje discusses how we can expect to see more drugs and new combinations utilized in the upfront setting, as approvals in the relapsed/refractory setting increase.

Dr. Kumar reviews a range of patient- and disease-related factors to consider when choosing therapies for NDMM including; transplant eligibility, renal function, and presence of extramedullary disease